Le Lézard
Classified in: Health
Subjects: SVY, TRI

Dr. Sabine Hazan Conducts ProgenaBiome's First Fecal Transplant for The Purposes of Studying Autism


VENTURA, Calif., Aug. 3, 2021 /PRNewswire/ -- Dr. Sabine Hazan, founder and CEO of ProgenaBiome, a state-of-the-art genetic research sequencing laboratory, traversed new frontiers in clinical research as she executed her first investigational use of Fecal Microbiota Transplant (FMT) as a potential treatment for an Autism patient last month.

The procedure was a familial FMT, with the patient's sister donating the sample that was used. It was completed as part of a clinical research study with FDA approval through an individual Investigational New Drug (IND) Application.

"I founded ProgenaBiome to continue the legacy work of world-famous infectious disease specialist Dr. Sydney Finegold," says Dr. Hazan, renowned gastroenterologist, leader in microbiome research, and co-author of Let's Talk S**t. "Dr. Finegold dedicated his life to studying the gut flora and its relationship to disease, particularly Autism. He told me 'the answer lies in the bacteria of the gut' and advised me to open a genetic sequencing research lab. As a result, ProgenaBiome was born, in an attempt to help find those answers."

Finegold was among the first to postulate a relationship between the gut microbiome and Autism. When Finegold passed away in 2018, he left decades of research and findings to Dr. Hazan, who has since sought to continue his work. With the success of this procedure, Dr. Hazan hopes to find new data on the potential connection between Autism and the microbiome.

Neurological diseases are hypothesized to potentially be related to gut dysbiosis, and in a previous successful procedures, Dr. Hazan completed a similar FMT for a patient for Alzheimer's disease. Following this success, Dr. Haan published promising data on the patient's post-FMT improvement: Rapid improvement in Alzheimer's disease symptoms following fecal microbiota transplantation. This breakthrough case led to a collaboration with Dr. Sheldon Jordan, a board-certified neurologist, and the publication of a book called REGENESIS: The Brain Doctor's Guide to Health, available on Amazon. This joint effort will lead to more INDs, where FMT will be considered for neurological diseases like Alzheimer's, Parkinson's, and Multiple Sclerosis.

Dr. Hazan and Dr. Jordan will continue their protocol on Autism and FMT on 30 more patients with hopes that it might be a turning point in healthcare solutions for patients with Autism, a condition that the CDC asserts has become increasingly prevalent in recent years.

Strategically placed as a genetic sequencing lab, site, contract research organization (CRO), and now sponsor, ProgenaBiome has 44+ ongoing clinical trials investigating the role of the gut flora in immunity and disease. To support its Mission, please support the Microbiome Research Foundation, a 501(c)(3) non-profit organization, dedicated to helping patients with diseases of the gut flora (microbiome).

For more, visit:
https://progenabiome.com 
https://clinicaltrials.gov 
https://microbiomeresearchfoundation.com/ 
https://letstalkshit.org/ 

Contact:
Stephanie Davis
[email protected] 

SOURCE ProgenaBiome


These press releases may also interest you

at 07:15
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") , InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise...

at 07:10
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended...

at 07:10
Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable...

at 07:05
Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the...

at 07:05
Seres Therapeutics, Inc. ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an...



News published on and distributed by: